CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to enhance RNA-based therapeutics by developing a novel delivery system called nanoVAST. This system targets specific cells without the drawbacks of viral vectors, enabling efficient and precise cargo delivery for potential clinical applications.
Cell-specific cargo delivery is a key remaining problem in the field of RNA-based therapeutics.
Thus far, delivery has relied on lipid nanoparticles (LNPs) which encapsulate RNA with high efficiency, but broadly lack in specificity.
Viral vectors are currently the only FDA approved tissue-specific cargo delivery option, with specificity being the result of manipulation of outer capsid proteins.
However, viral systems are also associated with drawbacks such as oncogenicity, antigenicity and pre-e…
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Heidelberg
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
